Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced a — dividend on Wednesday, December 4th, Wall Street Journal reports. Stockholders of record on Monday, December 16th will be given a dividend of 0.50 per share by the biopharmaceutical company on Monday, December 23rd. The ex-dividend date is Friday, December 13th.
MACK traded up $0.26 during midday trading on Wednesday, hitting $4.38. 157,200 shares of the company’s stock traded hands, compared to its average volume of 61,573. The stock’s fifty day simple moving average is $3.96 and its 200-day simple moving average is $5.35. Merrimack Pharmaceuticals has a one year low of $3.51 and a one year high of $7.50.
Separately, ValuEngine raised shares of Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 1st.
Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.
Recommended Story: S&P/ASX 200 Index
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.